Copyright West LLC. Minimum 15 minutes delayed.

News Release

<< Back
Jan 13, 2015

OvaScience Announces Closing of $132 Million Public Offering of Common Stock including Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2015-- OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 345,000 shares of common stock at the public offering price of $50.00 per share. The exercise of the underwriters’ option brought the total number of shares of common stock sold by OvaScience to 2,645,000 shares and increased the total gross proceeds raised in this offering to $132.3 million, before deducting the underwriting discounts, commissions and estimated expenses.

J.P. Morgan Securities LLC acted as lead book runner for the offering. Credit Suisse Securities (USA) LLC also acted as joint book runner for the offering. Leerink Partners LLC acted as co-manager for the offering. H.C. Wainwright & Co., LLC and Ladenburg Thalmann acted as advisors to the Company.

The public offering of common stock was made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC). A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: +1 (866) 803-9204.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global life sciences company dedicated to improving fertility for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit and connect with us on Twitter and Facebook.


Source: OvaScience

Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer